SGH
Sivik Global Healthcare Portfolio holdings
AUM
$224M
This Quarter Return
-11.22%
1 Year Return
+5.3%
3 Year Return
+45.33%
5 Year Return
+103.79%
10 Year Return
+430.94%
AUM
$253M
AUM Growth
+$253M
(-5.6%)
Cap. Flow
-$107M
Cap. Flow
% of AUM
-42.34%
Top 10 Holdings %
Top 10 Hldgs %
44%
Holding
60
New
10
Increased
18
Reduced
9
Closed
21
Top Buys
| 1 |
Cencora
COR
|
$12.6M |
| 2 |
Bristol-Myers Squibb
BMY
|
$11M |
| 3 |
McKesson
MCK
|
$9.22M |
| 4 |
Novo Nordisk
NVO
|
$8.16M |
| 5 |
Encompass Health
EHC
|
$7.73M |
Top Sells
| 1 |
Boston Scientific
BSX
|
$82.9M |
| 2 |
Tenet Healthcare
THC
|
$27.6M |
| 3 |
AbbVie
ABBV
|
$14M |
| 4 |
Baxter International
BAX
|
$12.5M |
| 5 |
Elevance Health
ELV
|
$8.31M |
Sector Composition
| 1 | Healthcare | 98.4% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Vertex Pharmaceuticals
VRTX
$100B
| $4.43M | 1.75% |
25,000
-7,500
| -23% | -$1.33M |
|
27
Eli Lilly
LLY
$657B
| $4.39M | 1.73% |
60,000
+10,000
| +20% | +$732K |
|
28
Select Medical
SEM
$1.61B
| $4.16M | 1.64% |
+80,000
| New | +$4.16M |
|
|
HRC
29
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
| $4.04M | 1.6% |
40,000
+20,100
| +101% | +$2.03M |
|
30
Charles River Laboratories
CRL
$8.04B
| $4.04M | 1.59% |
+15,000
| New | +$4.04M |
|
|
31
Boston Scientific
BSX
$156B
| $3.71M | 1.47% |
7,500
-167,500
| -96% | -$82.9M |
|
32
Thermo Fisher Scientific
TMO
$186B
| $3.59M | 1.42% |
100,000
+82,500
| +471% | +$2.96M |
|
33
Grifois
GRFS
$6.78B
| $3.53M | 1.39% |
175,000
-100,000
| -36% | -$2.01M |
|
|
34
AbbVie
ABBV
$372B
| $3.51M | 1.38% |
10,000
-40,000
| -80% | -$14M |
|
|
35
Baxter International
BAX
$12.7B
| $3.41M | 1.34% |
15,000
-55,000
| -79% | -$12.5M |
|
36
Zimmer Biomet
ZBH
$21B
| $2.52M | 1% |
20,000
-15,000
| -43% | -$1.89M |
|
|
37
Tenet Healthcare
THC
$16.3B
| $2.45M | 0.97% |
17,500
-197,500
| -92% | -$27.6M |
|
38
Steris
STE
$24.1B
| $280K | 0.11% |
+5,823
| New | +$280K |
|
39
Alcon
ALC
$39.5B
| – | – |
-45,000
| Closed | -$2.55M |
|
40
Align Technology
ALGN
$10.3B
| – | – |
-15,000
| Closed | -$4.19M |
|
41
Amgen
AMGN
$155B
| – | – |
-25,000
| Closed | -$6.03M |
|
42
Avantor
AVTR
$9.18B
| – | – |
-150,000
| Closed | -$2.72M |
|
43
Bio-Rad Laboratories Class A
BIO
$8.06B
| – | – |
-15,000
| Closed | -$5.55M |
|
|
BLUE
44
DELISTED
bluebird bio
BLUE
| – | – |
-20,000
| Closed | -$1.76M |
|
|
BPMC
45
DELISTED
Blueprint Medicines
BPMC
| – | – |
-18,520
| Closed | -$1.48M |
|
46
CRISPR Therapeutics
CRSP
$4.71B
| – | – |
-25,000
| Closed | -$1.52M |
|
47
Quest Diagnostics
DGX
$20.3B
| – | – |
-27,500
| Closed | -$2.94M |
|
|
48
Elevance Health
ELV
$71.8B
| – | – |
-27,500
| Closed | -$8.31M |
|
49
Edwards Lifesciences
EW
$47.8B
| – | – |
-15,000
| Closed | -$3.5M |
|
50
Illumina
ILMN
$15.8B
| – | – |
-10,000
| Closed | -$3.32M |
|